Acadian Asset Management LLC Cue Biopharma, Inc. Transaction History

Acadian Asset Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$1.77 - $3.09 $22,017 - $38,436	12,439 New	12,439 $23,000
Q4 2022 Feb 14, 2023	SELL	$2.39 - $3.95 $62,300 - $102,964	-26,067 Reduced 41.22%	37,167 $104,000
Q3 2022 Nov 14, 2022	BUY	$2.23 - $3.37 $141,011 - $213,098	63,234 New	63,234 $139,000
Q2 2020 Aug 12, 2020	SELL	$12.7 - $30.73 $381,622 - $923,405	-30,049 Closed	0 $0
Q1 2020 May 11, 2020	BUY	$9.85 - $22.27 $208,583 - $471,589	21,176 Added 238.66%	30,049 $426,000
Q4 2019 Feb 06, 2020	BUY	$7.06 - $17.47 $62,643 - $155,011	8,873 New	8,873 $141,000

14.1M

14.4K

2.6K

Ticker CUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,381,700
Market Cap $38.2M
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Acadian Asset Management LLC with notifications on news.